Michael A. White, Ph.D., serves as the Chief Scientific Officer at IDEAYA Biosciences Inc., a precision medicine oncology company. Dr. White is a renowned figure in the field of cancer biology and drug discovery, bringing a wealth of experience and expertise to his role. He earned his Ph.D. in Biochemistry from the University of California, Berkeley, and has since built an impressive career in academia and industry. Prior to joining IDEAYA Biosciences, Dr. White held several key positions that have shaped his approach to scientific leadership. He was a Professor of Cell Biology at the University of Texas Southwestern Medical Center, where he led a research program focused on understanding the molecular mechanisms of cancer and developing novel therapeutic strategies. His work has been published in numerous high-impact scientific journals, and he has received several awards for his contributions to cancer research. Dr. White also served as the Chief Scientific Officer at Eutropics Pharmaceuticals, where he played a pivotal role in advancing the company's pipeline of oncology drug candidates. As Chief Scientific Officer at IDEAYA Biosciences, Dr. White is responsible for overseeing the company's research and development efforts, guiding the scientific strategy, and driving the discovery and development of innovative cancer therapies. His leadership has been instrumental in advancing IDEAYA's synthetic lethality approach to precision oncology, which aims to identify and exploit vulnerabilities in cancer cells. Under his guidance, the company has made significant progress in its clinical programs and continues to expand its portfolio of promising drug candidates. Dr. White's vision and expertise are key drivers of IDEAYA's mission to deliver transformative treatments to patients with cancer.